Coronavirus Disease 2019 (COVID-19) Outbreak, Update # 16

**Remdesivir**

**Key Points and Recommendations:**

- The NH Department of Health and Human Services (DHHS) is receiving a small supply of remdesivir from the federal government and will distribute it proportionally (based on COVID-19 case counts) to hospitals that affirm willingness and capacity to manage this medication under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

- The EUA permits the use of remdesivir for the treatment of hospitalized adult and pediatric patients with severe COVID-19.

- Remdesivir is an investigational direct acting antiviral drug that inhibits viral RNA synthesis and has demonstrated *in-vitro* activity against SARS-CoV-2 with preliminary data showing that remdesivir may shorten the time to recovery and possibly decrease mortality in adult patients hospitalized with COVID-19.

- Clinicians managing patients for whom remdesivir is appropriate under the FDA EUA, and who have access to remdesivir through their hospital pharmacies, must review the following information and requirements before treating patients:
  - [FDA EUA for remdesivir](#)
  - [Frequently Asked Questions on the EUA of remdesivir](#)
  - [Fact Sheet for health care providers](#)
  - [Fact Sheet for patients and parent/caregivers](#)

- The [Fact Sheet for health care providers](#) contains important information about who may receive remdesivir under the FDA EUA, preparation and storage information, dosing and administration instructions, and other specific instructions for health care providers and mandatory requirements for administration.

- Initial supply of remdesivir will be limited, so hospitals and clinicians should decide who will be prioritized for remdesivir based on their patients and current supply. DHHS will notify participating hospitals immediately on receipt of drug.

- Please join us **Monday May 11th from 12:00-1:00 pm** for a review of remdesivir, including practical insights from colleagues at Dartmouth-Hitchcock Medical Center who have been using remdesivir under a clinical trial study protocol. To participate:
  - [Zoom link](#): Click [here](#)
  - [Call-in Number](#): 1-646-558-8656
  - [Meeting ID](#): 960 2810 6667
  - [Password](#): 720813
Additional Information

- NH DHHS COVID-19 website: https://www.nh.gov/covid19/

- For any questions regarding this notification, please call the NH DHHS, DPHS, Bureau of Infectious Disease Control at (603) 271-4496 during business hours (8:00 a.m. – 4:30 p.m.).
- If you are calling after hours or on the weekend, please call the New Hampshire Hospital switchboard at (603) 271-5300 and request the Public Health Professional on-call.
- To change your contact information in the NH Health Alert Network, please send an email to DHHS.Health.Alert@dhhs.nh.gov.

Status: Actual
Message Type: Update
Severity: Moderate
Sensitivity: Not Sensitive
Message Identifier: NH-HAN 20200510 COVID-19 Update #16
Delivery Time: 12 hours
Acknowledgement: No
Distribution Method: Email, Fax
Distributed to: Physicians, Physician Assistants, Practice Managers, Infection Control Practitioners, Infectious Disease Specialists, Community Health Centers, Hospitals, Hospital CEOs, Hospital Emergency Departments, EMS, Nurses, NHHA, Pharmacists, Laboratory Response Network, Manchester Health Department, Nashua Health Department, Public Health Networks, DHHS Outbreak Team, DPHS Investigation Team, DPHS Management Team, Northeast State Epidemiologists, Zoonotic Alert Team, Health Officers, Deputy Health Officers, MRC, NH Schools, EWIDS, Dialysis & Transplant Clinics, STD Clinics, Immunization Practices, Travel Centers, Influenza Sentinels, Urgent Care Centers, Ambulatory Surgical Centers, Walk-in Clinics, Poison Center, Alcohol and Other Drug Treatment Centers, Long-Term Care Facilities, Community Mental Health Centers, Health Departments, Internal Medicine, Occupational Health, Gastroenterology, Schools and Daycare Providers, Regional Public Health Networks, Environmental Services, Family Planning Programs, Department of Corrections, Home Care Providers, Local and State Partners, Area Agencies

From: Benjamin P. Chan, MD, MPH, State Epidemiologist
Originating Agency: NH Department of Health and Human Services, Division of Public Health
Attachments: None